Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

0.8880 +0.0680 (+8.29%)
Streaming Delayed Price Updated: 11:28 AM EDT, Sep 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Seres Therapeutics (NASDAQ:MCRB) brought in sales totaling $7.22 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 173.3%, resulting in a... 
Via Benzinga
Seres Therapeutics: Q4 Earnings Insights
Seres Therapeutics (NASDAQ:MCRB) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Earnings Preview: Seres Therapeutics
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit
From Seres Therapeutics
Via Business Wire
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
Seres Therapeutics Inc (NASDAQ: MCRB) has announced the publication of data from Phase 3 ECOSPOR III study SER-109 for recurrent C. difficile infection (... 
Via Benzinga
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study
Seres Therapeutics Inc (NASDAQ: MCRB) announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate... 
Via Benzinga
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
From Seres Therapeutics, Inc.
Via Business Wire
Jim Cramer Shares His Thoughts On Novavax, ViacomCBS And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Seres Therapeutics, Inc. (NASDAQ: 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
Via Benzinga
Exposures Product Safety
Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday
The biotech stock announced it had enrolled its first patient in a trial for one of its therapies. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
35 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an... 
Via Benzinga
Exposures Product Safety
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Looking Into Seres Therapeutics's Return On Capital Employed
According to Benzinga Pro, during Q3, Seres Therapeutics (NASDAQ:MCRB) earned $68.41 million, a 242.09% increase from the preceding quarter. Seres Therapeutics also posted a total... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Tumbles 300 Points; PubMatic Shares Gain After Q3 Results
Toward the end of trading Wednesday, the Dow traded down 0.67% to 36,075.12 while the NASDAQ fell 1.90% to 15,585.20. The S&P also fell, dropping 0.99% to 4,638.64. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 31.29% to $9.02 during Wednesday's regular session. Trading volume for this security as of 12:30 EST... 
Via Benzinga
76 Biggest Movers From Yesterday
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Morning Market Update: Markets Edge Lower; US Inflation Rate Increases To 6.2%
Following the market opening Wednesday, the Dow traded down 0.07% to 36,293.80 while the NASDAQ fell 0.23% to 15,850.04. The S&P also fell, dropping 0.05% to 4,682.75. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6... 
Via Benzinga
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
From Seres Therapeutics
Via Business Wire
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.